Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Dec;16(6):829–832. doi: 10.1128/aac.16.6.829

Amikacin pharmacokinetics in pediatric patients with malignancy.

T G Cleary, L K Pickering, W G Kramer, S Culbert, L S Frankel, S Kohl
PMCID: PMC352961  PMID: 533263

Abstract

The pharmacokinetics of amikacin were evaluated in 50 pediatric patients (1 to 17 years of age) with malignancies and normal renal function. Dosage regimens of 5 mg/kg per dose were administered intravenously (i) over 30 min every 8 h, (ii) over 60 min every 8 h, and (iii) over 60 min every 6 h. Administration of amikacin over 30 min produced concentrations in serum of 29.3 +/- 5.7 micrograms/ml at the end of the infusion and subtherapeutic concentrations 4 h after the infusion. The regimen of 20 mg/kg per 24 h, divided into doses given every 6 h infused over 60 min, achieved concentrations in serum at the end of the infusion of 17.2 +/- 1.7 micrograms/ml and at 6 h of 1.2 +/- 0.3 microgram/ml. The serum half-life was 1.24 +/- 0.09 h, volume of distribution was 0.26 +/- 0.02 liter/kg, and total body clearance rate was 131 +/- 10 ml/min per 1.73 m2. No accumulation of amikacin was noted, and no significant side effects could be attributed to the drug. This study suggests that the optimal initial dosage regimen of amikacin in children is 20 mg/kg per 24 h administered in equal doses every 6 h over 60 min; however, optimal therapy requires individualization of dosage based on measured serum concentrations and susceptibility data on bacterial pathogens isolated.

Full text

PDF
829

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F., Witchitz J. L., Goldstein F., Talbot J. N., Le Goffic F. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns. J Infect Dis. 1976 Nov;134(Suppl):S280–S285. doi: 10.1093/infdis/135.supplement_2.s280. [DOI] [PubMed] [Google Scholar]
  2. Anderson E. T., Young L. S., Hewitt W. L. Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med. 1976 Oct;61(4):493–497. doi: 10.1016/0002-9343(76)90328-4. [DOI] [PubMed] [Google Scholar]
  3. Cabana B. E., Taggart J. G. Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans. Antimicrob Agents Chemother. 1973 Apr;3(4):478–483. doi: 10.1128/aac.3.4.478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clarke J. T., Libke R. D., Regamey C., Kirby W. M. Comparative pharmacokinetics of amikacin and kanamycin. Clin Pharmacol Ther. 1974 Jun;15(6):610–616. doi: 10.1002/cpt1974156610. [DOI] [PubMed] [Google Scholar]
  5. Evans W. E., Feldman S., Ossi M., Taylor R. H., Chaudhary S., Melton E. T., Barker L. F. Gentamicin dosage in children: a randomized prospective comparison of body weight and body surface area as dose determinants. J Pediatr. 1979 Jan;94(1):139–143. doi: 10.1016/s0022-3476(79)80380-7. [DOI] [PubMed] [Google Scholar]
  6. Finland M., Garner C., Wilcox C., Sabath L. D. Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics. J Infect Dis. 1976 Nov;134(Suppl):S297–S307. doi: 10.1093/infdis/135.supplement_2.s297. [DOI] [PubMed] [Google Scholar]
  7. Haas M. J., Davies J. Enzymatic acetylation as a means of determining serum aminoglycoside concentrations. Antimicrob Agents Chemother. 1973 Oct;4(4):497–499. doi: 10.1128/aac.4.4.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hoecker J. L., Pickering L. K., Swaney J., Kramer W. G., van Eys J., Feldman S., Kohl S. Clinical pharmacology of tobramycin in children. J Infect Dis. 1978 May;137(5):592–596. doi: 10.1093/infdis/137.5.592. [DOI] [PubMed] [Google Scholar]
  9. Howard J. B., McCracken G. H., Jr Pharmacological evaluation of amikacin in neonates. Antimicrob Agents Chemother. 1975 Jul;8(1):86–90. doi: 10.1128/aac.8.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Höffler D., Koeppe P., Demers H. G. Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function. J Infect Dis. 1976 Nov;134(Suppl):S369–S373. doi: 10.1093/infdis/135.supplement_2.s369. [DOI] [PubMed] [Google Scholar]
  11. Kawaguchi H., Naito T., Nakagawa S., Fujisawa K. I. BB-K 8, a new semisynthetic aminoglycoside antibiotic. J Antibiot (Tokyo) 1972 Dec;25(12):695–708. doi: 10.7164/antibiotics.25.695. [DOI] [PubMed] [Google Scholar]
  12. Khan A. J., Evans H. E., Jhaveri R., Chang C. T., Hochstein L. Amikacin pharmacokinetics in the therapy of childhood urinary tract infection. Pediatrics. 1976 Dec;58(6):873–876. [PubMed] [Google Scholar]
  13. Kirby W. M., Clarke J. T., Libke R. D., Regamey C. Clinical pharmacology of amikacin and kanamycin. J Infect Dis. 1976 Nov;134(Suppl):S312–S315. doi: 10.1093/infdis/135.supplement_2.s312. [DOI] [PubMed] [Google Scholar]
  14. Knothe H. In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin. J Infect Dis. 1976 Nov;134(Suppl):S271–S274. doi: 10.1093/infdis/135.supplement_2.s271. [DOI] [PubMed] [Google Scholar]
  15. Lode H., Grunert K., Koeppe P., Langmaack H. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J Infect Dis. 1976 Nov;134(Suppl):S316–S322. doi: 10.1093/infdis/135.supplement_2.s316. [DOI] [PubMed] [Google Scholar]
  16. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pennington J. E., Dale D. C., Reynolds H. Y., MacLowry J. D. Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis. 1975 Sep;132(3):270–275. doi: 10.1093/infdis/132.3.270. [DOI] [PubMed] [Google Scholar]
  18. Price K. E., DeFuria M. D., Pursiano T. A. Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates. J Infect Dis. 1976 Nov;134(Suppl):S249–S261. doi: 10.1093/infdis/135.supplement_2.s249. [DOI] [PubMed] [Google Scholar]
  19. Sardemann H., Colding H., Hendel J., Kampmann J. P., Hvidberg E. F., Vejlsgaard R. Kinetics and dose calculations of amikacin in the newborn. Clin Pharmacol Ther. 1976 Jul;20(1):59–66. doi: 10.1002/cpt197620159. [DOI] [PubMed] [Google Scholar]
  20. Smith C. R., Baughman K. L., Edwards C. Q., Rogers J. F., Lietman P. S. Controlled comparison of amikacin and gentamicin. N Engl J Med. 1977 Feb 17;296(7):349–353. doi: 10.1056/NEJM197702172960701. [DOI] [PubMed] [Google Scholar]
  21. Valdivieso M., Feld R., Rodriguez V., Bodey G. P. Amikacin therapy of infections in neutropenic patients. Am J Med Sci. 1975 Nov-Dec;270(3):453–463. doi: 10.1097/00000441-197511000-00006. [DOI] [PubMed] [Google Scholar]
  22. Vogelstein B., Kowarski A., Lietman P. S. The pharmacokinetics of amikacin in children. J Pediatr. 1977 Aug;91(2):333–339. doi: 10.1016/s0022-3476(77)80847-0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES